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5.251e-6) downregulated in EBV-positive compared to EBV-
negative PTLD [Bim: 6/40 (15%), cleaved PARP: 10/43 (23%), 
vs. Bim: 13/16 (81%), cleaved PARP: 12/17 (71%)]. Additionally, 
we observed a tendency toward increased Bcl-2 protein ex-
pression (p = 0.24) in EBV-positive PTLD. Hence, we provide 
evidence of a distinct regulation of Bcl-2 family proteins in 
EBV-positive versus negative PTLD. The low-expression pat-
tern of the proapoptotic proteins Bim and cleaved PARP to-
gether with the high-expression pattern of the antiapoptot-
ic protein Bcl-2 by trend in EBV-positive tumor cells suggests 
disruption of the apoptotic pathway by EBV in PTLD, promot-
ing survival signals in the host cells. 
 Copyright © 2012 S. Karger AG, Basel 
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 Abstract 
 Posttransplant lymphoproliferative disorders (PTLD) repre-
sent a spectrum of lymphoid diseases complicating the clin-
ical course of transplant recipients. Most PTLD are Epstein-
Barr virus (EBV) associated with viral latency type III. Several 
in vitro studies have revealed an interaction between EBV 
latency proteins and molecules of the apoptosis pathway. 
Data on human PTLD regarding an association between Bcl-
2 family proteins and EBV are scarce. We analyzed 60 prima-
ry PTLD for expression of 8 anti- (Bcl-2, Bcl-XL, and Mcl-1) and 
proapoptotic proteins (Bak and Bax), the so-called BH3-only 
proteins (Bad, Bid, Bim, and Puma), as well as the apoptosis 
effector cleaved PARP by immunohistochemistry. Bim and 
cleaved PARP were both significantly (p = 0.001 and p = 
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 Introduction 
 Posttransplant lymphoproliferative disorders (PTLD) 
represent a spectrum of lymphoid diseases complicating 
the clinical course of transplant recipients  [1–3] . Most 
PTLD are of B cell lineage and frequently arise from ex-
tranodal sites and at different time points after transplan-
tation  [3, 4] . The risk factors include the solid organ
recipient’s age, the type of organ transplanted, the host 
Epstein-Barr virus (EBV) infection status before trans-
plantation, and the immunosuppressive therapy  [4, 5] . 
PTLD are clinically, morphologically, and biologically 
heterogeneous diseases, including early EBV-linked, 
mostly polyclonal lesions and true, monoclonal EBV-pos-
itive or negative lymphomas  [5] ; these different lesions are 
classified according to the current 2008 World Health Or-
ganization Classification of Hematopoietic and Lymphoid 
Tumors into early lesions including infectious mononu-
cleosis-like lesions (IM) and plasmacytic hyperplasia, 
polymorphic PTLD, and monomorphic PTLD reaching 
the criteria of lymphoma  [3, 5–8] . In earlier studies, 44–
90% of PTLD were reported to be EBV associated, and 
analysis of EBV latent gene expression identified latency 
type III infection in almost all EBV-infected PTLD  [9, 10] . 
EBV is an oncogenic gamma herpesvirus that asymptom-
atically infects more than 90% of the general population. 
In vitro studies have evidenced the ability of EBV to infect 
and transform primary B cells into lymphoblastoid cell 
lines (LCLs) inducing a pattern of viral gene expression 
known as latency type III  [11] . It has been demonstrated 
that only 6 of the viral latency proteins (EBNA1, –2, 3A, 
–3C, LP, and LMP1) are essential for efficient transforma-
tion of B cells into LCLs  [11, 12] . The first viral gene to be 
transcribed after infection is EBNA2, which is a potent 
trans-activator of LMP1 and LMP2A, and numerous cel-
lular genes, including cMYC  [11, 13] . LMP1 is function-
ally similar to CD40, acts as a constitutively activated re-
ceptor, and can activate NF-kb signaling and downstream 
genes, such as the antiapoptotic Blf-1 gene and Bcl-xL  [13] . 
Moreover, Bcl-2 (B cell lymphoma 2), an antiapoptotic 
protein expressed in a broad range of lymphomas, is up-
regulated in vitro by LMP-1. Bcl-2 family members are 
critical regulators of programmed cell death  [14] . Deregu-
lation of Bcl-2 family proteins has been implicated in the 
development of many malignancies, and it has been shown 
to be related to tumor progression, poor prognosis, and 
clinical resistance to anticancer therapy  [15] . Bcl-2 pro-
teins can be divided into three groups: antiapoptotic 
members (including Bcl-2, Bcl-xL, and Mcl-1), proapop-
totic proteins (including Bax and Bak) directly involved 
in the release of apoptotic factors from the mitochondria, 
and the so-called BH3-only proteins (which share homol-
ogy only within the third Bcl-2 homology domain, BH3) 
 [16] . The BH3-only proteins may interact with and inhib-
it the antiapoptotic activity of Bcl-2 or Bcl-xL or directly 
activate the proapoptotic Bax or Bak proteins  [17] . At least 
9 mammalian BH3-only proteins have been identified to 
date (Bad, Bik, Blk, Hrk, Bid, Bim, Noxa, PUMA, and 
Bmf)  [18] . Among these BH3-only proteins, Bim (Bcl-2 
interacting mediator of cell death) plays a major role in the 
control of apoptosis in immune cells (including normal 
and tumoral lymphocytes)  [19] .
 Bim activity may be regulated at both the transcrip-
tional level and the posttranscriptional level  [20] . Three 
different pathways of Bim regulation were recently re-
ported in experimental models of EBV+ lymphoprolif-
erations  [21–23] . Clybouw et al.  [21] found that EBV in-
fection can lead to downregulation of the proapoptotic 
molecule Bim in Burkitt lymphoma cell lines via ERK ac-
tivation. Inomata et al.  [22] reported an additional mech-
anism of apoptotic pathway regulation; their work showed 
that microRNA are involved in cell survival regulation, 
including Bim expression, and that unbalanced miRNA 
synthesis is frequently found in lymphoproliferations. In 
2009, Paschos et al.  [23] reported that some specific EBV 
proteins (such as EBNA3A and 3C) could directly induce 
Bim suppression by promoter methylation. In spite of 
these advances in EBV-host interaction in vitro, few stud-
ies have been carried out on EBV-associated human lym-
phoma tissues. To gain insight into EBV-linked tumori-
genesis, we investigated posttransplant lymphoprolifera-
tive diseases as models to understand the viral-host 
interaction in tumor development. We therefore ana-
lyzed the protein expression of pro- and antiapoptotic 
molecules by immunohistochemistry. In particular, we 
tested in a series of adult and pediatric PTLD the follow-
ing molecules possibly targeted by viral products: Bcl-2, 
Bcl-xl, Mcl-1 (antiapoptotic); Bak, Bax, Bid, Bim, and 
PUMA (proapoptotic), and cleaved PARP (Poly-ADP Ri-
bosePolymerase), one of the main cleavage targets of cas-
pase 3, a marker of effective apoptosis.
 Materials and Methods 
 Patients
 Lymphoproliferations from a total of 60 organ transplant re-
cipients with a diagnosis of PTLD were studied. They were re-
trieved from the files of three institutions as follows: 27 cases from 
the Institute of Surgical Pathology, University Hospital Zürich 
(Zürich, Switzerland), 25 cases from Bicêtre/Paul Brousse Univer-
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sity Hospitals (Le Kremlin-Bicêtre and Villejuif, France), and 8 
cases from Pavia University Hospital (Pavia, Italy). The study was 
accepted by the respective local ethical authorities. We focused 
exclusively on B cell PTLD.
 Histopathology, Immunohistochemical Analysis, and EBV
in situ Hybridization 
 All tumor specimens were formalin fixed and paraffin embed-
ded. Prior to the study, hematoxylin and eosin (H&E)-stained 
whole sections were reviewed by four pathologists, and PTLD 
were classified according to WHO classification criteria  [3] . 
Monoclonal antibodies against proapoptotic proteins were ap-
plied for immunohistochemistry using standard protocols ( ta-
ble 1 ). The EBV latency status was established by applying anti-
bodies against LMP1 and EBNA2 in addition to EBER in situ
hybridization (see below) ( table  1 ). Pretreatment was custom -
ized according to the manufacturer’s instructions ( table 1 ) and 
performed in a microwave on whole sections and/or TMA. Im-
munodetection was performed with EnVision TM + Dual Link
Sys tem-HRP (Dako, Glostrup, Denmark) employing 3,3  -di-
aminobenzidine/H 2 O 2 as a chromogen. Each case was evaluated 
independently (M.R.G. and T.R.) for the percentage of positive 
cells by visual estimation and recorded in 10% increments for 
each antibody. Disagreements were resolved by joint review on a 
multi-head microscope. PTLD were considered positive when at 
least 20% of tumor cells expressed pro- or antiapoptotic proteins.
 The EBV status was assessed by in situ hybridization (ISH) 
analysis using a fluorescein isothiocyanate (FITC)-labeled peptic 
nucleic acid (PNA) probe, complementary to the EBV-encoded 
RNAs (EBERs) (PNA ISH Detection Kit; Dako).
 Statistical Analysis 
 Statistical association between protein expression in EBV-pos-
itive versus negative PTLD was tested using a two-sided Fisher’s 
exact test and Bonferroni correction. p  ! 0.05 was considered sta-
tistically significant. Statistical analysis was performed using the 
software package SPSS  (version 12.0.1 for Windows  ;  © SPSS 
Inc., Chicago, Ill., USA).
 Results 
 Patients 
 The clinical features of the patients with B cell PTLD 
included in this study are summarized in  table 2 . Twelve 
children or adolescents ( ! 18 years of age) and 48 adults 
(19 female and 41 male patients) were recipients of differ-
ent organ transplants. Most patients (54; 90%) received 
Table 1.  Panel of monoclonal antibodies used in the study
Antigen Manufacturer Dilution Pretreatment
EBV latency proteins
LMP1 Dako 1/80 citrate 40’
EBNA2 Dako 1/100 EDTA 40’
Antiapoptotic proteins
Bcl-2 Dako 1/100 EDTA 40’
Bcl-xl ZYMED 1/50 EDTA 40’
Mcl-1 Santa Cruz 1/500 EDTA 30’
Proapoptotic proteins
Bax Dako 1/500 EDTA 40’
Bak BD 1/250 EDTA 40’
PUMA Cell Signaling 1/400 EDTA 30’
Bim ABcam 1/400 EDTA 30’
Bid Santa Cruz 1/100 EDTA 30’
Cleaved PARP ABcam 1/100 EDTA 30’
Table 2.  Comparison of clinical features between EBV-positive 
and EBV-negative PTLD
Clinical features EBV+ EBV–
Sex
Male 29 12
Female 14 5
Age, years
Median 40 63
Range 1–63 35–75
<18 12 0
≥18 31 17
Interval, months
Median 22 52
Onset
Early 19 0
Late 24 17
Transplant
Liver 14 12
Heart 10 3
Lung 6 1
Kidney 7 1
Kidney/pancreas 2 0
Kidney/liver 1 0
Kidney/heart 0 1
Heart/lung 1 0
Bone marrow 1 0
Tumor site
Lymph node 12 11
Lung 8 1
Small bowel 7 3
Liver 5 2
Kidney 3 0
Heart 2 0
Soft tissue 1 0
Adrenal gland 1 0
Brain 1 0
Peritoneum 1 0
Nasal cavity 1 0
Skin 1 0
Histology
DLBCL 20 15
BL 2 0
P-PTLD 19 2
IM-like 2 0
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single organ transplantation, whereas 5 patients got dou-
ble solid organ transplantation and 1 patient received an 
allogeneic bone marrow transplantation. Among patients 
with single organ transplantation, the organ most fre-
quently transplanted was the liver (26; 48%), followed by 
the heart (13; 24%), kidney (8; 15%), and lung (7; 13%).
 The median age at transplantation was 40 years (range 
1–75). The latency period between transplantation and 
PTLD onset ranged from 1 to 168 months. According to 
the definition of Armitage et al.  [7] , 19 PTLDs were clas-
sified as early onset PTLD ( ^  12 months from transplan-
tation) and the remaining 41 as late onset PTLD ( 1 12 
months).
 Histology 
 The histopathological diagnoses according to 2008 
WHO criteria are summarized in  table  2 . Most of B-
PTLD in this series were monomorphic (37 cases, 62%) 
and high grade with a prevalence of classical DLBCL as 
well as two Burkitt lymphomas (BL). Twenty-one cases 
(35%) represented polymorphic PTLD (P-PTLD) consist-
ing of a spectrum of B cells including mature B lympho-
cytes, lymphoplasmacytoid cells, plasma cells, and
immunoblasts, and the two remaining cases (3%) were 
consistent with early lesions with an infectious mononu-
cleosis-like pattern (IM), such as paracortical expansion 
and numerous immunoblasts in a background of T cells 
and plasmocytes.
 Immunohistochemical Findings 
 EBV Status and Latency Pattern 
 Forty-three of 60 (72%) PTLD were EBV positive as 
determined by the expression of EBERs. The EBV latency 
type was assessed by LMP1 and EBNA2 in 24 EBV+ cas-
es. Twenty-one EBV+ PTLD case showed a type III 
(LMP1+, EBNA2+) latency pattern (88%), 1 EBV+ PTLD 
case showed type II (LMP1+, EBNA2–) latency, and the 2 
remaining EBV+ PTLD cases showed a type I (LMP1–, 
EBNA2–) latency pattern.
 EBV Status and Disease Onset 
 The time period between transplantation and PTLD 
onset was much shorter in EBV-positive cases than in 
negative cases, with a median interval of 22 months 
(range 2–156) in the EBV-positive cases compared to a 
median of 52 months (range 21–168) in the EBV-negative 
ones.
 Expression of Apoptosis-Related Molecules 
 The immunohistochemical findings in relationship to 
EBV status are summarized in  table 3 .
 In the EBV-positive PTLD group, Bcl-2 was expressed 
in a total of 30 of 43 cases (70%). Only 2 of 40 lymphomas 
(5%) were positive for Bcl-xl and all analyzable PTLD ex-
pressed Mcl 1. Twenty-two of 41 cases (54%) expressed 
Bax; 35 of 38 cases (92%) expressed Bak, only 6 of 40 
PTLD cases (15%) expressed Bim ( fig.  1 ), and 12 of 43 
PTLD cases (28%) expressed PUMA. All analyzable cases 
expressed Bid. Cleaved PARP was found to be positive in 
10 of 43 cases (23%).
 In the EBV-negative PTLD group, antiapoptotic pro-
teins were expressed as follows: Bcl-2 in 9 of 17 cases 
(53%), Bcl-xl in 4 of 17 cases (24%), and Mcl-1 in all cases 
(100%). The proapototic proteins Bax, Bim, Puma, Bid, 
and Bak were respectively expressed in 11/17 cases (65%), 
13/16 cases (81%), 5/17 cases (29%), 15/17 (88%), and 15/17 
(88%); cleaved PARP was positive in 12 cases (71%). 
 Taken together, the expressions of the proapoptotic 
protein, BH3 only, Bim, and the apoptosis effector mol-
ecule cleaved PARP were significantly (p  ! 0.05 by Fish-
er’s exact test and Bonferroni correction) downregulated 
in EBV-positive PTLD compared to EBV-negative ones. 
On the contrary, the expression of antiapoptotic proteins 
(Bcl2, Bcl-xL, and Mcl1) as well as the remaining pro-
apoptotic proteins such as Bax and Bak Puma, Bad, and 
Bid did not show any significant differences (p  ! 0.05). 
Table 3.  Upregulated apoptotic proteins in relation to EBV status, 
independent of the latency type
Positive PTLD (number of
c ases/total number of analyzed 
cases), %
p value p value 
(Bonfer-
roni cor-
rected)
EBV– EBV+  
Proapoptotic
Bak 88 (15/17) 92 (35/38) 0.639 5.754
Bax 65 (11/17) 54 (22/41) 0.564 5.073
Bid 88 (15/17) 100 (42/42) 0.079 0.715
Bim 81 (13/16) 15 (6/40) 5.251 ! 
10–6
4.726 ! 
10–5
Effector
PARP 71 (12/17) 23 (10/43) 0.001
Puma 28 (5/17) 28 (12/43) 1 9
Antiapoptotic
Bcl-2 53 (9/17) 70 (30/43) 0.243 2.188
Bcl-xl 24 (4/17) 5 (2/40) 0.058 0.525
Mcl-1 100 (17/17) 100 (43/43) 1 9
The number of evaluable cases varied due to loss of tissue or 
unstainability.
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Interestingly, however, there was at least a tendency to-
ward a higher Bcl-2 expression in EBV-positive compared 
to EBV-negative PTLD (p = 0.24). Particularly, Bcl-2 was 
expressed in a high percentage of EBV latency type III 
(87%) cases as compared to latency I and latency II types 
or EBV negative lymphoproliferations (p = 0.47). This lat-
ter observation underlines the role of EBV in Bcl-2 up-
regulation since most PTLD in this series are indeed of 
latency type III.
 Discussion 
 In this study we analyzed a large series of sixty B cell 
PTLD, the majority (72%) of which were EBV associated 
as determined by EBER in situ hybridization. Although 
it is well established that EBV plays a crucial role in the 
development of PTLD, the mechanism of interaction 
with the host cells was fairly unknown in humans. We 
investigated 9 pro- and antiapoptotic proteins in pri-
mary lymphoma tissues. By immunohistochemistry we 
revealed a distinct staining pattern in the EBV-positive 
group with a low-expression pattern of the proapoptot-
ic protein Bim and the apoptosis effector cleaved PARP 
as well as a high-expression pattern of Bcl-2, particu-
larly in EBV latency type III cases. Hence, our results 
strongly suggest that EBV promotes prosurvival signals 
in host cells by interfering with the apoptosis pathway. 
Interestingly, the staining pattern is independent of 
PTLD histology, the time lag between disease onset and 
transplantation, patient age, and transplanted organs, 
suggesting a robust association with the viral infection. 
The most important role seems to be advocated to Bim, 
which is a critical regulator of lymphocyte survival, and 
EBV negative EBV positive
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 Fig. 1. Summary of the characteris-
tic staining pattern in EBV-positive ver-
sus EBV-negative monomorphic PTLDs 
(DLBCL). EBV-negative example showing 
a high expression of the proapoptotic pro-
teins BIM and cleaved PARP and no ex-
pression of the antiapoptotic protein Bcl-2, 
whereas the opposite is true for EBV-posi-
tive PTLD. 
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its reduced expression is associated with lymphomagen-
esis in mice and humans  [24] . The monoclonal antibody 
used in our study was generated using a synthetic pep-
tide corresponding to residues in exon 2 of human Bim. 
It recognizes all known splice variants of Bim, but no 
other Bcl-2 family members. In normal tonsil B cells, the 
three major Bim isoforms are strongly associated with 
the antiapoptotic Bcl-2 family members Mcl-1, Bcl-2, 
and Bcl-xL  [25] . The Mcl-1/Bim complex is the most 
abundant among the three types of complexes  [26] . 
Modification of the Mcl-1/Bim complex might be caused 
by modification of Bim and/or Mcl-1 protein levels or by 
a complete or partial dissociation of the Mcl-1/Bim di-
mer  [27] . In our PTLD series, Mcl-1 was found to be 
equally expressed in all analyzable PTLD, independent-
ly of the EBV status. This is an additional argument in 
favor of prosurvival signals since Mcl-1 expression is 
crucial for the development and viability of hematopoi-
etic cells and a decrease in its expression leads to cell 
death  [28] . Moreover, it supports the assumption of a 
disrupted apoptotic balance specifically targeting Bim 
in EBV+ PTLD.
 Several control mechanisms downregulating Bim ex-
pression are currently known: through ERK phosphory-
lation and proteasome degradation  [21] , through the 
miRNA system  [22] , and via the EBV proteins EBNA3A 
and 3C through promoter gene methylation  [23] . It is 
worth mentioning that in our series all EBV+ PTLD 
showing a low-expression pattern of Bim displayed an 
EBV latency type III program, suggesting a role of
EBNA3A and 3C in methylation of the Bim promotor.
 In this study, we analyzed the expression of cleaved 
PARP as an effector of apoptosis control. Cleaved PARP 
is involved in DNA repair and maintenance of genomic 
integrity, regulation of protein expression through a 
posttranscriptional mechanism (such as inflammatory 
mediators), and apoptosis, through caspase cleavage  [29] . 
Depending on the severity of the DNA damage, geno-
toxic stimuli can trigger different pathways; whereas in 
mild DNA damage cleaved PARP induces DNA repair 
and thus survival, more severe DNA damage provokes 
apoptotic cell death by the induction of caspases cleavage 
leading to fragmentation of cleaved PARP into two sub-
units (p89 and p24)  [30] . In our series, a low percentage 
of cells expressing cleaved PARP was observed in EBV-
positive PTLD, reflecting a decreased level of apoptosis in 
this group.
 Puma, a proapoptotic protein transcriptionally upreg-
ulated by p53 and activated by p53-dependent apoptotic 
stimuli did not reach any significant difference between 
the two PTLD groups (12 of 43 EBV+ PTLD and 5 of 17 
EBV– PTLD Puma-positive cases). However, a tendency 
toward lower expression levels in the EBV-positive group 
was observed. This tendency is concordant with lowered 
Bim expression in the presence of EBV.
 Bcl-2, an antiapoptotic protein, showed a tendency 
toward increased expression in EBV-positive PTLD in 
general and of EBV latency type III in particular in our 
series. This is in line with the notion that Bcl-2 is up-
regulated in immortalized lymphoblastoid B cells of 
EBV latency type III and in EBV-positive PTLD via 
LMP1  [31, 32] . However, for restriction of tissue, EBV 
latency could be assessed in only half of the EBV-posi-
tive PTLD in our study. For this reason, we are unable 
to draw affirmative conclusions on the putative influ-
ence viral proteins and particularly LMP1 might have 
on Bcl-2 expression of EBV carrying tumor cells. More-
over, Bcl-2 protein was detectable in 53% of EBV-nega-
tive cases, suggesting that different mechanisms partic-
ipate in its upregulation in PTLD. Nevertheless, given its 
antiapoptotic function and its role in conferring resis-
tance to chemotherapeutic agents, Bcl-2 represents an 
interesting therapeutic target in the PTLD setting. No-
tably, it was shown that Bcl-2 antisense enhances the in 
vitro and in vivo response of EBV-associated lympho-
proliferative diseases to the anti-CD 20 antibody ritu-
ximab  [33] , a treatment which is frequently considered 
in PTLD patients and has been shown to be effective in 
other B cell malignancies (reviewed by Masood et al. 
 [34] ). Recent studies on new generation molecules with 
anti-Bcl-2 reactivity report on their potentiating role of 
chemotherapeutic activity, as well as on anti-CD 20 an-
tibody, making this easily applicable molecule an ideal 
predictive marker  [35] .
 In summary, we demonstrate a specific expression 
pattern of apoptosis pathway-related molecules promot-
ing cell survival in EBV-infected PTLD cells. Our results 
further suggest an important role of the proapoptotic 
protein Bim in the disruption of apoptosis by EBV.
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